Research And Development Expense of Ascendis Pharma A/S from 31 Dec 2015 to 31 Dec 2024

Taxonomy & unit
ifrs-full: EUR
Summary
Ascendis Pharma A/S annual and quarterly Research And Development Expense in EUR history and change rate from 31 Dec 2015 to 31 Dec 2024.
  • Ascendis Pharma A/S Research And Development Expense for the quarter ending 30 Sep 2024 was €73,544,000, a 34% decline year-over-year.
  • Ascendis Pharma A/S annual Research And Development Expense for 2024 was €307,004,000, a 26% decline from 2023.
  • Ascendis Pharma A/S annual Research And Development Expense for 2023 was €413,454,000, a 8.9% increase from 2022.
  • Ascendis Pharma A/S annual Research And Development Expense for 2022 was €379,624,000, a 28% increase from 2021.
Source SEC data
View on sec.gov
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Change (%)
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Change (%)

Ascendis Pharma A/S Annual Research And Development Expense (EUR)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 €307,004,000 -€106,450,000 -26% 01 Jan 2024 31 Dec 2024 20-F 12 Feb 2025 2024 FY
2023 €413,454,000 +€33,830,000 +8.9% 01 Jan 2023 31 Dec 2023 20-F 12 Feb 2025 2024 FY
2022 €379,624,000 +€83,757,000 +28% 01 Jan 2022 31 Dec 2022 20-F 12 Feb 2025 2024 FY
2021 €295,867,000 +€34,963,000 +13% 01 Jan 2021 31 Dec 2021 20-F 07 Feb 2024 2023 FY
2020 €260,904,000 +€69,283,000 +36% 01 Jan 2020 31 Dec 2020 20-F 16 Feb 2023 2022 FY
2019 €191,621,000 +€51,340,000 +37% 01 Jan 2019 31 Dec 2019 20-F 02 Mar 2022 2021 FY
2018 €140,281,000 +€40,692,000 +41% 01 Jan 2018 31 Dec 2018 20-F 10 Mar 2021 2020 FY
2017 €99,589,000 +€33,567,000 +51% 01 Jan 2017 31 Dec 2017 20-F 03 Apr 2020 2019 FY
2016 €66,022,000 +€25,494,000 +63% 01 Jan 2016 31 Dec 2016 20-F 03 Apr 2019 2018 FY
2015 €40,528,000 01 Jan 2015 31 Dec 2015 20-F 28 Mar 2018 2017 FY

Ascendis Pharma A/S Quarterly Research And Development Expense (EUR)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 €73,544,000 -€37,895,000 -34% 01 Jul 2024 30 Sep 2024 6-K 14 Nov 2024 2024 Q3
Q1 2024 €378,027,000 €70,687,000 -€35,427,000 -33% 01 Jan 2024 31 Mar 2024 6-K 02 May 2024 2024 Q1
Q4 2023 €413,454,000 €90,880,000 -€17,737,000 -16% 01 Oct 2023 31 Dec 2023 20-F 12 Feb 2025 2024 FY
Q3 2023 €431,191,000 €111,439,000 +€14,008,000 +14% 01 Jul 2023 30 Sep 2023 6-K 14 Nov 2024 2024 Q3
Q2 2023 €417,183,000 €105,021,000 +€14,638,000 +16% 01 Apr 2023 30 Jun 2023 6-K 05 Sep 2023 2023 Q2
Q1 2023 €402,545,000 €106,114,000 +€22,921,000 +28% 01 Jan 2023 31 Mar 2023 6-K 02 May 2024 2024 Q1
Q4 2022 €379,624,000 €108,617,000 +€42,966,000 +65% 01 Oct 2022 31 Dec 2022 20-F 12 Feb 2025 2024 FY
Q3 2022 €336,658,000 €97,431,000 +€38,670,000 +66% 01 Jul 2022 30 Sep 2022 6-K 07 Nov 2023 2023 Q3
Q2 2022 €297,988,000 €90,383,000 +€7,077,000 +8.5% 01 Apr 2022 30 Jun 2022 6-K 05 Sep 2023 2023 Q2
Q1 2022 €290,911,000 €83,193,000 -€4,956,000 -5.6% 01 Jan 2022 31 Mar 2022 6-K 27 Apr 2023 2023 Q1
Q4 2021 €295,867,000 €65,651,000 -€10,101,000 -13% 01 Oct 2021 31 Dec 2021 20-F 07 Feb 2024 2023 FY
Q3 2021 €305,968,000 €58,761,000 -€5,298,000 -8.3% 01 Jul 2021 30 Sep 2021 6-K 02 Nov 2022 2022 Q3
Q2 2021 €311,266,000 €83,306,000 +€19,728,000 +31% 01 Apr 2021 30 Jun 2021 6-K 10 Aug 2022 2022 Q2
Q1 2021 €291,538,000 €88,149,000 +€30,634,000 +53% 01 Jan 2021 31 Mar 2021 6-K 11 May 2022 2022 Q1
Q4 2020 €260,904,000 €75,752,000 +€25,474,000 +51% 01 Oct 2020 31 Dec 2020 20-F 16 Feb 2023 2022 FY
Q3 2020 €235,430,000 €64,059,000 +€17,801,000 +38% 01 Jul 2020 30 Sep 2020 6-K 10 Nov 2021 2021 Q3
Q2 2020 €217,629,000 €63,578,000 +€19,752,000 +45% 01 Apr 2020 30 Jun 2020 6-K 27 Aug 2021 2021 Q2
Q1 2020 €197,877,000 €57,515,000 +€6,256,000 +12% 01 Jan 2020 31 Mar 2020 6-K 27 May 2021 2021 Q1
Q4 2019 €191,621,000 €50,278,000 +€12,283,000 +32% 01 Oct 2019 31 Dec 2019 20-F 02 Mar 2022 2021 FY
Q3 2019 €179,338,000 €46,258,000 +€14,747,000 +47% 01 Jul 2019 30 Sep 2019 6-K 12 Nov 2020 0
Q2 2019 €164,591,000 €43,826,000 +€3,591,000 +8.9% 01 Apr 2019 30 Jun 2019 6-K 27 Aug 2020 2020 Q2
Q1 2019 €161,000,000 €51,259,000 +€20,719,000 +68% 01 Jan 2019 31 Mar 2019 6-K 19 May 2020 2020 Q1
Q4 2018 €140,281,000 €37,995,000 +€9,961,000 +36% 01 Oct 2018 31 Dec 2018 20-F 10 Mar 2021 2020 FY
Q3 2018 €130,320,000 €31,511,000 +€2,444,000 +8.4% 01 Jul 2018 30 Sep 2018 6-K 18 Nov 2019 2019 Q3
Q2 2018 €127,876,000 €40,235,000 +€18,355,000 +84% 01 Apr 2018 30 Jun 2018 6-K 28 Aug 2019 2019 Q2
Q1 2018 €109,521,000 €30,540,000 +€9,932,000 +48% 01 Jan 2018 31 Mar 2018 6-K 30 May 2019 2019 Q1
Q4 2017 €99,589,000 €28,034,000 01 Oct 2017 31 Dec 2017 20-F 03 Apr 2020 2019 FY
Q3 2017 €29,067,000 01 Jul 2017 30 Sep 2017 6-K 28 Nov 2018 2018 Q3
Q2 2017 €21,880,000 01 Apr 2017 30 Jun 2017 6-K 29 Aug 2018 2018 Q2
Q1 2017 €20,608,000 01 Jan 2017 31 Mar 2017 6-K 30 May 2018 2018 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.